PharmExec Staff

The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and reductions in surgery and systemic corticosteroid use.

Part three of our three-part webinar series airs live tonight at 7 p.m. ET, unpacking how most favored nation pricing, import tariffs and direct-to-consumer channels could ripple through payer contracts, 340B and practice economics.

Join us for a premium webinar on November 4, 2025!

“This is about building a powerful bridge between the science that transforms lives and the systems that deliver that transformation,” said Michael J. Hennessy Jr., MJH Life Sciences chairman and CEO, of the BPD Healthcare acquisition.

Join us for this premium webinar on September 10!

Vinay Prasad returns to lead the FDA's CBER after leaving in late July.

Vinay Prasad, MD, MPH, departs FDA's Center for Biologics, citing family time and avoiding distraction.

With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.

“We’re going to tariff our pharmaceuticals, and once we do that, they are going to come rushing back into our country," President Donald J. Trump said during a Tuesday night dinner in Washington.

Eli Lilly CEO David Ricks to the BBC: “It feels like it'll be hard to come back from here."

The 2017 GPS ranking evaluates clinical trial registration, results reporting, clinical study report synopsis sharing, and journal article publication rates for new drugs approved by the Food and Drug Administration in 2014 that were sponsored by large drug companies.

Combined company will have market value of around $18 billion, reports Reuters.

March 23, 2016.

PharmExec talks to babylon founder and CEO Ali Parsa on how technology will deliver healthcare services to patients globally.

February 17, 2015.

February 17, 2015.

The pharma, medical and biotech sector accounted for the top three announced deals of the year in the EMEA region in 2014.

The French pharmaceutical market is forecast to grow at a "tepid" CAGR of 0.7% from $46.2 billion in 2014 to $48.2 billion by 2020, according to GlobalData.

An expert CPhI Worldwide panel has identified "the good, the bad, and the ugly" in its forecast for the pharmaceutical industry for 2015.

Findings from the joint report on the occurrence of antimicrobial resistance in bacteria from humans and food-producing animals.

The European Hantavirus diagnostics market is growing at a CAGR of 5.8 percent, outperforming the U.S. market, which registered 3.7 percent.

Glaxo SmithKline (GSK) has announced that Sir Philip Hampton has been appointed Chairman of the Nominations Committee, effective today (January 27).

According to experts on Pharm Exec's Editorial Advisory Board, 2015 is set to be another interesting year from a consolidation perspective.